RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cytokine network in immunosuppression and tumor development in glioblastoma.
Cytokine network in immunosuppression and tumor development in glioblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胶质母细胞瘤(GBM)仍然是最具侵袭性的原发性脑肿瘤之一,具有深度免疫抑制的微环境。细胞因子、趋化因子和生长因子是这种免疫抑制的核心,它们损害 T 细胞、NK 细胞、树突状细胞的功能,并促进调节性免疫细胞群的募集。
重要的是,这些可溶性介质还直接作用于胶质瘤细胞,增强其增殖、存活、侵袭和对治疗的抵抗。本章概述了 GBM 中细胞因子驱动通路的复杂网络,强调其免疫抑制功能和肿瘤内在效应,并讨论其对治疗干预的意义。TGF-β 和 IL-10 等关键因子因其在调节免疫应答和促进肿瘤生长中的双重作用而受到重点关注,而其他细胞因子,包括 IL-6、IL-1β 和 CXCL12,则促成了一个高度动态且冗余的信号环境。I 型和 II 型干扰素传统上被视为抗肿瘤因子,但在慢性暴露下表现出矛盾效应,促进免疫耗竭和抑制性免疫检查点上调。鉴于 GBM 中细胞因子网络的复杂性和适应性,单靶点策略取得的成功有限。未来的治疗需要采用系统层面的方法,同时破坏多条通路,并考虑肿瘤微环境的空间和时间异质性,以实现持久的临床应答。
Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with a profoundly immunosuppressive microenvironment. Cytokines, chemokines, and growth factors are central to this immunosuppression, impairing the function of T cells, NK cells, dendritic cells, and promoting the recruitment of regulatory immune populations.
Importantly, these soluble mediators also act directly on glioma cells, enhancing their proliferation, survival, invasion, and resistance to therapy. This chapter outlines the intricate network of cytokine-driven pathways in GBM, emphasizing their immunosuppressive functions and tumor-intrinsic effects, and discusses their implications for therapeutic intervention. Key factors such as TGF-β and IL-10 are highlighted for their dual roles in modulating immune responses and promoting tumor growth, while other cytokines, including IL-6, IL-1β, and CXCL12, contribute to a highly dynamic and redundant signaling environment.
Type I and II interferons, traditionally seen as antitumoral, are shown to have paradoxical effects under chronic exposure, promoting immune exhaustion and inhibitory immune checkpoint upregulation. Given the complexity and adaptability of cytokine networks in GBM, single-target strategies have had limited success. Future therapies will need to adopt a systems-level approach, simultaneously disrupting multiple pathways and considering the spatial and temporal heterogeneity of the tumor microenvironment to achieve durable clinical responses.
MEMBER ACCOUNT
登录成功会直接打开下一页。